JP2020510627A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510627A5 JP2020510627A5 JP2019531975A JP2019531975A JP2020510627A5 JP 2020510627 A5 JP2020510627 A5 JP 2020510627A5 JP 2019531975 A JP2019531975 A JP 2019531975A JP 2019531975 A JP2019531975 A JP 2019531975A JP 2020510627 A5 JP2020510627 A5 JP 2020510627A5
- Authority
- JP
- Japan
- Prior art keywords
- drugs
- therapeutic agent
- pharmaceutical composition
- fatty liver
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 33
- 229940124597 therapeutic agent Drugs 0.000 claims 18
- 229940079593 drug Drugs 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 208000010706 fatty liver disease Diseases 0.000 claims 12
- 208000004930 Fatty Liver Diseases 0.000 claims 11
- 206010019708 Hepatic steatosis Diseases 0.000 claims 11
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 11
- 102000013566 Plasminogen Human genes 0.000 claims 7
- 108010051456 Plasminogen Proteins 0.000 claims 7
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 210000004185 liver Anatomy 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000037157 Azotemia Diseases 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims 3
- 230000007882 cirrhosis Effects 0.000 claims 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 201000006370 kidney failure Diseases 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 208000009852 uremia Diseases 0.000 claims 3
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 2
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 claims 2
- 230000002924 anti-infective effect Effects 0.000 claims 2
- 239000003416 antiarrhythmic agent Substances 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 229940127219 anticoagulant drug Drugs 0.000 claims 2
- 239000003472 antidiabetic agent Substances 0.000 claims 2
- 239000002220 antihypertensive agent Substances 0.000 claims 2
- 229940127088 antihypertensive drug Drugs 0.000 claims 2
- 229940127218 antiplatelet drug Drugs 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 230000003177 cardiotonic effect Effects 0.000 claims 2
- 230000008021 deposition Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000002934 diuretic Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000003527 fibrinolytic agent Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 2
- 239000011251 protective drug Substances 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- 229940124549 vasodilator Drugs 0.000 claims 2
- 239000003071 vasodilator agent Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims 1
- 208000015163 Biliary Tract disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims 1
- 208000017701 Endocrine disease Diseases 0.000 claims 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010037601 Pyelonephritis chronic Diseases 0.000 claims 1
- 206010061481 Renal injury Diseases 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 206010060755 Type V hyperlipidaemia Diseases 0.000 claims 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 239000000496 cardiotonic agent Substances 0.000 claims 1
- 208000003167 cholangitis Diseases 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 201000006368 chronic pyelonephritis Diseases 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 230000035622 drinking Effects 0.000 claims 1
- 208000030172 endocrine system disease Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 208000020694 gallbladder disease Diseases 0.000 claims 1
- 208000018914 glucose metabolism disease Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 229940124622 immune-modulator drug Drugs 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 208000021510 thyroid gland disease Diseases 0.000 claims 1
- 229940034208 thyroxine Drugs 0.000 claims 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016110168 | 2016-12-15 | ||
| CNPCT/CN2016/110168 | 2016-12-15 | ||
| CNPCT/CN2016/110172 | 2016-12-15 | ||
| CN2016110172 | 2016-12-15 | ||
| PCT/CN2017/089047 WO2018107688A1 (zh) | 2016-12-15 | 2017-06-19 | 一种预防和治疗脂肪肝的方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510627A JP2020510627A (ja) | 2020-04-09 |
| JP2020510627A5 true JP2020510627A5 (https=) | 2020-07-30 |
| JP7214225B2 JP7214225B2 (ja) | 2023-01-30 |
Family
ID=62557882
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019532070A Active JP7158740B2 (ja) | 2016-12-15 | 2017-06-19 | 冠状動脈アテローム性硬化症およびその合併症を治療するための方法 |
| JP2019532071A Active JP7161217B2 (ja) | 2016-12-15 | 2017-06-19 | アテローム性動脈硬化症およびその合併症を予防するための方法 |
| JP2019531975A Active JP7214225B2 (ja) | 2016-12-15 | 2017-06-19 | 脂肪肝を予防および治療するための方法 |
| JP2019532073A Active JP7160351B2 (ja) | 2016-12-15 | 2017-06-19 | 脂肪代謝障害およびその関連疾患を予防および治療するための方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019532070A Active JP7158740B2 (ja) | 2016-12-15 | 2017-06-19 | 冠状動脈アテローム性硬化症およびその合併症を治療するための方法 |
| JP2019532071A Active JP7161217B2 (ja) | 2016-12-15 | 2017-06-19 | アテローム性動脈硬化症およびその合併症を予防するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019532073A Active JP7160351B2 (ja) | 2016-12-15 | 2017-06-19 | 脂肪代謝障害およびその関連疾患を予防および治療するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20190328850A1 (https=) |
| EP (4) | EP3556391A4 (https=) |
| JP (4) | JP7158740B2 (https=) |
| CN (4) | CN110366425A (https=) |
| CA (4) | CA3046664C (https=) |
| TW (9) | TW202123963A (https=) |
| WO (8) | WO2018107688A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI624268B (zh) * | 2015-12-18 | 2018-05-21 | Talengen Institute Of Life Sciences Co Ltd | 纖溶酶原在製備藥劑上的用途及包括纖溶酶原之藥劑 |
| US11207387B2 (en) | 2016-12-15 | 2021-12-28 | Talengen International Limited | Method and drug for preventing and treating obesity |
| JP7175270B2 (ja) | 2016-12-15 | 2022-11-18 | タレンゲン インターナショナル リミテッド | グルカゴン、インスリンを正常なバランスに戻らせる方法 |
| US11154595B2 (en) | 2016-12-15 | 2021-10-26 | Talengen International Limited | Method for preventing and treating pulmonary fibrosis |
| WO2018107688A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗脂肪肝的方法 |
| WO2018107707A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种改善心脏病变的方法 |
| CA3067890A1 (en) * | 2017-06-19 | 2018-12-27 | Talengen International Limited | Method for regulating and controling glp-1/glp-1r and drug |
| DK4112069T3 (da) * | 2020-02-26 | 2025-09-29 | Talengen Int Ltd | Komponenter i plasminogen-aktiveringsvejen til brug ved behandling af forhøjet blodtryk |
| CA3176941A1 (en) * | 2020-03-24 | 2021-09-30 | Talengen International Limited | Method and medicine for treating huntington's disease |
| CN115697385A (zh) * | 2020-05-11 | 2023-02-03 | 泰伦基国际有限公司 | 一种治疗脊髓性肌萎缩症的方法和药物 |
| CN112056563A (zh) * | 2020-09-15 | 2020-12-11 | 王胜林 | 用于修复脂质代谢障碍的营养素组合物及其应用 |
| CN113041247A (zh) * | 2021-04-21 | 2021-06-29 | 中山大学孙逸仙纪念医院 | 伊玛替尼在防治新型冠状病毒及并发症药物中的应用 |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4245051A (en) | 1978-03-30 | 1981-01-13 | Rockefeller University | Human serum plasminogen activator |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4658830A (en) | 1984-08-08 | 1987-04-21 | Survival Technology, Inc. | Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms |
| DE3515869A1 (de) | 1985-05-03 | 1986-11-13 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung optisch aktiver azolderivate |
| JPS62153224A (ja) | 1985-12-27 | 1987-07-08 | Green Cross Corp:The | プラスミノゲン製剤 |
| GB8721951D0 (en) | 1987-09-18 | 1987-10-28 | Thrombosis Research Trust | Organic compounds |
| JP2764264B2 (ja) | 1987-10-01 | 1998-06-11 | 株式会社ミドリ十字 | 線溶活性増強剤 |
| AT402367B (de) | 1990-10-11 | 1997-04-25 | Immuno Ag | Pharmazeutische zubereitung auf basis von lys-plasminogen |
| AU4661493A (en) * | 1992-07-01 | 1994-01-31 | Beth Israel Hospital Boston | Enhancement of thrombolytic therapy with deglycosylated plasminogen |
| US5520912A (en) | 1993-07-02 | 1996-05-28 | Immuno Aktiengesellschaft | Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen |
| DK125693D0 (https=) | 1993-11-05 | 1993-11-05 | Novo Nordisk As | |
| DE4411143C2 (de) | 1994-03-30 | 1996-08-01 | Immuno Ag | Thrombosemittel |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| EP1001985A1 (en) | 1997-06-26 | 2000-05-24 | Karolinska Innovations AB | Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo |
| US7317003B2 (en) | 1998-09-04 | 2008-01-08 | National University Of Singapore | Small peptides having anti-angiogenic and endothelial cell inhibition activity |
| US6465424B1 (en) | 1999-02-17 | 2002-10-15 | Bristol-Myers Squibb Company | Anti-angiogenic agent and method for inhibiting angiogenesis |
| WO2000049871A1 (en) | 1999-02-24 | 2000-08-31 | Henry Ford Health System | An anti-angiogenic kringle protein and its mutants |
| US6899877B2 (en) | 1999-03-09 | 2005-05-31 | Minu, L.L.C. | Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina |
| US6964764B2 (en) | 1999-11-13 | 2005-11-15 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| US7544500B2 (en) | 1999-11-13 | 2009-06-09 | Talecris Biotherapeutics, Inc. | Process for the production of a reversibly inactive acidified plasmin composition |
| US20020159992A1 (en) | 2000-09-29 | 2002-10-31 | Jack Henkin | Antiangiogenic polypeptides and methods for inhibiting angiogenesis |
| US20030054988A1 (en) * | 2000-11-02 | 2003-03-20 | Weidong-Richard Ji | Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors |
| WO2003014145A2 (en) | 2001-08-10 | 2003-02-20 | Novartis Ag | Peptides that bind to atherosclerotic lesions |
| US7067492B2 (en) * | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
| CN1408431A (zh) | 2001-09-21 | 2003-04-09 | 北京华兴生生物技术有限公司 | 治疗与新生血管生成相关疾病的基因工程药物 |
| US7202066B2 (en) | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
| AU2003210137A1 (en) * | 2002-02-06 | 2003-09-02 | N-Zyme Biotec Gmbh | Method for producing recombinant proteins in micro-organisms |
| DE10390418D2 (de) * | 2002-02-06 | 2005-01-13 | N Zyme Biotec Gmbh | Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen |
| US20030199464A1 (en) | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
| EP1509236A4 (en) | 2002-05-13 | 2008-07-30 | Children S Hospital Los Angele | TREATMENT AND PREVENTION OF ABNORMAL SCALING IN KELOIDS AND OTHER SKIN OR INTERNAL WOUNDS OR LESIONS |
| BR0310100A (pt) | 2002-05-17 | 2007-04-27 | Esperion Therapeutics Inc | métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto |
| CN101518533A (zh) | 2002-12-06 | 2009-09-02 | 法布罗根股份有限公司 | 脂肪调节 |
| ATE430731T1 (de) | 2002-12-10 | 2009-05-15 | Wyeth Corp | Substituierte indoloxoacetylaminoessigsäurederivate als inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1) |
| CN1451746A (zh) | 2003-03-20 | 2003-10-29 | 广州市启源生物科技有限公司 | 人纤溶酶原Kringle 5缺失突变重组多肽 |
| WO2005026127A1 (ja) | 2003-09-11 | 2005-03-24 | Institute Of Medicinal Molecular Design. Inc. | プラスミノゲンアクチベータインヒビター－１阻害剤 |
| US20080017694A1 (en) | 2003-09-24 | 2008-01-24 | Alexander Schnell | Braze Alloy And The Use Of Said Braze Alloy |
| JP4740531B2 (ja) | 2003-09-30 | 2011-08-03 | 雪印乳業株式会社 | 骨吸収抑制剤 |
| CN102660564B (zh) | 2004-04-22 | 2013-05-08 | 泰勒克里斯生物治疗学公司 | 重组修饰的纤溶酶 |
| US8357147B2 (en) | 2005-08-17 | 2013-01-22 | Spinal Restoration, Inc. | Method for repairing intervertebral discs |
| FR2882654B1 (fr) * | 2005-03-01 | 2007-04-27 | Servier Lab | Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques |
| WO2006095713A1 (ja) | 2005-03-08 | 2006-09-14 | Institute Of Medicinal Molecular Design. Inc. | プラスミノゲンアクチベータインヒビター－１阻害剤 |
| CA2602946A1 (en) * | 2005-03-22 | 2006-09-28 | Medstar Health, Inc. | Delivery systems and methods for diagnosing and treating cardiovascular diseases |
| US20060257391A1 (en) | 2005-05-11 | 2006-11-16 | Bausch & Lomb Incorporated | Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions |
| US20090123582A1 (en) | 2006-03-24 | 2009-05-14 | Akiko Kuwahara | Ameliorating Agent for Metabolic Syndrome |
| AU2007290881B2 (en) | 2006-08-28 | 2013-03-07 | Omnio Healer Ab | Candidates against infection |
| US20100028321A1 (en) | 2006-08-28 | 2010-02-04 | Omnio Healer Ab | Drug target for preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
| WO2008051794A2 (en) | 2006-10-20 | 2008-05-02 | Dow Global Technologies Inc. | Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome |
| CN101219219B (zh) | 2007-01-10 | 2013-02-13 | 北京普罗吉生物科技发展有限公司 | 包含血管抑素或其片段的复合物、其制备方法及应用 |
| CN101015686B (zh) | 2007-02-06 | 2010-05-19 | 中国人民解放军军事医学科学院基础医学研究所 | 一种溶栓药物增效剂及其制备方法 |
| US20080200387A1 (en) | 2007-02-15 | 2008-08-21 | Hua-Lin Wu | Anti-angiogenic protein, composition and use thereof |
| AR067446A1 (es) | 2007-07-11 | 2009-10-14 | Otsuka Pharma Co Ltd | Un medicamento para tratar higado graso que comprende cilostazol |
| AT505574B1 (de) * | 2007-08-10 | 2009-09-15 | Affiris Forschungs & Entwicklungs Gmbh | Mimotope zur behandlung von atherosklerose |
| US20090239868A1 (en) | 2007-10-23 | 2009-09-24 | Institute Of Medical Molecular Design, Inc. | Inhibitor of pai-1 production |
| CN101842093B (zh) | 2007-10-23 | 2012-08-22 | 株式会社医药分子设计研究所 | Pai-1产生抑制剂 |
| PL2220221T3 (pl) * | 2007-11-29 | 2015-07-31 | Grifols Therapeutics Inc | Rekombinacyjnie zmodyfikowana plazmina |
| CA2711878A1 (en) | 2008-01-09 | 2009-07-16 | Intrexon Corporation | Therapeutic inhibitors of pai-1 function and methods of their use |
| US20090208448A1 (en) | 2008-02-15 | 2009-08-20 | Solomon Keith R | Inhibition of angiogenesis |
| US20100209350A1 (en) * | 2008-12-30 | 2010-08-19 | Andreas Pfuetzner | Biomarkers for Adipose Tissue Activity |
| WO2010083570A1 (en) | 2009-01-23 | 2010-07-29 | The University Of Sydney | Novel metabolic disease therapy |
| CA2757615C (en) * | 2009-03-31 | 2018-07-17 | Renascience Co., Ltd. | Plasminogen activator inhibitor-1 inhibitor |
| EP2424561A2 (en) | 2009-04-30 | 2012-03-07 | Catherine Blondel | Methods for treating ocular conditions |
| WO2011004011A1 (en) | 2009-07-10 | 2011-01-13 | Thrombogenics Nv | Variants of plasminogen and plasmin |
| CN105031605A (zh) | 2009-08-12 | 2015-11-11 | 康奈尔大学 | 预防或治疗代谢综合症的方法 |
| CN101628113B (zh) | 2009-08-18 | 2012-01-04 | 南京农业大学 | 蚯蚓纤溶酶抗肝纤维化的应用 |
| CN101897925B (zh) | 2009-12-16 | 2015-04-29 | 成都百康医药工业药理毒理研究院 | 一种治疗代谢综合症的药物组合物 |
| WO2011139974A2 (en) | 2010-05-03 | 2011-11-10 | Abbott Laboratories | Anti-pai-1 antibodies and methods of use thereof |
| US9044458B2 (en) * | 2010-08-09 | 2015-06-02 | The Johns Hopkins University | Inhibition of tat activating regulatory DNA-binding protein 43 |
| CN102121023B (zh) | 2010-12-22 | 2012-07-04 | 中山大学 | 突变型人纤溶酶原kringle5及其制备方法及应用 |
| JP6085568B2 (ja) | 2011-01-05 | 2017-02-22 | スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ | プラスミノーゲンおよびプラスミンの変異体 |
| CN102154253A (zh) | 2011-01-06 | 2011-08-17 | 郑州大学 | 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途 |
| WO2012109097A1 (en) * | 2011-02-10 | 2012-08-16 | Trustees Of Dartmouth College | Methods for increasing plasmin activity and promoting plaque regression in the treatment of atherosclerosis |
| MX2013010076A (es) | 2011-03-03 | 2014-04-07 | Tersus Pharmaceuticals Llc | Composiciones y metodos que comprenden c16:1n7 palmitoleato. |
| CN102199587B (zh) | 2011-03-24 | 2013-06-19 | 广东药学院 | 人纤溶酶原功能性突变体及其制备方法和应用 |
| MX2013011294A (es) | 2011-03-30 | 2014-10-06 | Univ Texas | Metodos y composiciones para dirigir celulas adiposas en mamiferos. |
| CN102188699A (zh) | 2011-05-06 | 2011-09-21 | 南京农业大学 | 一种治疗动脉粥样硬化的药物组合物及其制备方法和应用 |
| US20120058537A1 (en) | 2011-07-27 | 2012-03-08 | Fereidoun Mahboudi | Chimeric truncated and mutant variant of tissue plasminogen activator (t-pa) resistant to plasminogen activator inhibitor-1 |
| US9644196B2 (en) | 2011-08-12 | 2017-05-09 | Thrombogenics Nv | Plasminogen and plasmin variants |
| CN102532326B (zh) * | 2011-11-18 | 2017-06-09 | 南京大学 | 一种肿瘤靶向的人纤溶酶原Kringle5变体及其应用 |
| CN103656630B (zh) | 2012-09-11 | 2015-07-08 | 江苏仁寿药业有限公司 | 一种提纯动物药材中纤溶酶并制备成中药组合物的方法 |
| DK2914575T3 (da) | 2012-10-31 | 2021-01-18 | Univ Michigan Regents | Plasminogen-aktivator-1-inhibitorer og fremgangsmåder til anvendelse deraf |
| WO2014160275A2 (en) | 2013-03-14 | 2014-10-02 | Battell Memorial Institute | Biomarkers for liver fibrosis |
| TWI689490B (zh) | 2013-03-15 | 2020-04-01 | 英商邊緣生物科技有限公司 | 用於治療纖維化之經取代之芳族化合物及相關方法 |
| CN105008320A (zh) * | 2013-03-20 | 2015-10-28 | 埃莱万斯可再生能源科学股份有限公司 | 烷基酯和羧酸的酸催化低聚 |
| CN104274449A (zh) | 2013-07-11 | 2015-01-14 | 无锡信达医疗器械有限公司 | 治疗肥胖症的药物组合物 |
| TW201734054A (zh) | 2013-08-13 | 2017-10-01 | 賽諾菲公司 | 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途 |
| TN2016000048A1 (en) | 2013-08-13 | 2017-07-05 | Sanofi Sa | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof |
| WO2015026494A2 (en) | 2013-08-20 | 2015-02-26 | Trustees Of Dartmouth College | Methods for treating tissue fibrosis |
| PY1577621A (es) | 2014-12-19 | 2017-10-02 | Prometic Biotherapeutics Inc | Composicion farmaceutica que comprende plasminogeno y uso para el mismo |
| TWI801331B (zh) | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| WO2017101867A1 (zh) | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防或治疗糖尿病性神经损伤及其相关病症的方法 |
| WO2017101870A1 (zh) | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防或治疗糖尿病性视网膜病变的方法 |
| WO2017101869A1 (zh) * | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗肝组织损伤及其相关病症的方法 |
| CA3008185C (en) | 2015-12-18 | 2024-01-16 | Talengen International Limited | Method for prevention or treatment of acute and chronic thrombosis |
| TWI725092B (zh) | 2015-12-18 | 2021-04-21 | 大陸商深圳瑞健生命科學硏究院有限公司 | 纖溶酶原在製備預防或治療糖尿病腎病或其相關病症之藥劑上的用途 |
| TWI624268B (zh) * | 2015-12-18 | 2018-05-21 | Talengen Institute Of Life Sciences Co Ltd | 纖溶酶原在製備藥劑上的用途及包括纖溶酶原之藥劑 |
| WO2018107688A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗脂肪肝的方法 |
| US11207387B2 (en) | 2016-12-15 | 2021-12-28 | Talengen International Limited | Method and drug for preventing and treating obesity |
| WO2018107707A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种改善心脏病变的方法 |
| TWI868051B (zh) | 2017-06-23 | 2025-01-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
-
2017
- 2017-06-19 WO PCT/CN2017/089047 patent/WO2018107688A1/zh not_active Ceased
- 2017-06-19 WO PCT/CN2017/089045 patent/WO2018107686A1/zh not_active Ceased
- 2017-06-19 TW TW110105040A patent/TW202123963A/zh unknown
- 2017-06-19 CA CA3046664A patent/CA3046664C/en active Active
- 2017-06-19 WO PCT/CN2017/089046 patent/WO2018107687A1/zh not_active Ceased
- 2017-06-19 CA CA3047168A patent/CA3047168A1/en active Pending
- 2017-06-19 CN CN201780078105.0A patent/CN110366425A/zh active Pending
- 2017-06-19 US US16/470,174 patent/US20190328850A1/en not_active Abandoned
- 2017-06-19 EP EP17881831.6A patent/EP3556391A4/en active Pending
- 2017-06-19 CA CA3047167A patent/CA3047167A1/en not_active Abandoned
- 2017-06-19 CN CN201780078127.7A patent/CN110114083A/zh active Pending
- 2017-06-19 CN CN201780078118.8A patent/CN110167583A/zh active Pending
- 2017-06-19 US US16/469,611 patent/US20190351033A1/en not_active Abandoned
- 2017-06-19 TW TW106120465A patent/TWI750189B/zh active
- 2017-06-19 EP EP17882244.1A patent/EP3556393A4/en active Pending
- 2017-06-19 TW TW106120491A patent/TW201822805A/zh unknown
- 2017-06-19 TW TW106120492A patent/TWI746580B/zh active
- 2017-06-19 TW TW106120498A patent/TW201822809A/zh unknown
- 2017-06-19 US US16/469,599 patent/US11547746B2/en active Active
- 2017-06-19 JP JP2019532070A patent/JP7158740B2/ja active Active
- 2017-06-19 TW TW106120499A patent/TW201822810A/zh unknown
- 2017-06-19 JP JP2019532071A patent/JP7161217B2/ja active Active
- 2017-06-19 JP JP2019531975A patent/JP7214225B2/ja active Active
- 2017-06-19 TW TW106120464A patent/TWI684459B/zh active
- 2017-06-19 CA CA3047169A patent/CA3047169A1/en not_active Abandoned
- 2017-06-19 EP EP17882245.8A patent/EP3556394A4/en active Pending
- 2017-06-19 JP JP2019532073A patent/JP7160351B2/ja active Active
- 2017-06-19 WO PCT/CN2017/089044 patent/WO2018107685A1/zh not_active Ceased
- 2017-06-19 WO PCT/CN2017/089049 patent/WO2018107690A1/zh not_active Ceased
- 2017-06-19 US US16/469,618 patent/US11478535B2/en active Active
- 2017-06-19 WO PCT/CN2017/089043 patent/WO2018107684A1/zh not_active Ceased
- 2017-06-19 WO PCT/CN2017/089051 patent/WO2018107691A1/zh not_active Ceased
- 2017-06-19 TW TW106120501A patent/TW201822812A/zh unknown
- 2017-06-19 TW TW106120463A patent/TWI680764B/zh active
- 2017-06-19 CN CN201780078126.2A patent/CN110114082A/zh active Pending
- 2017-06-19 WO PCT/CN2017/089052 patent/WO2018107692A1/zh not_active Ceased
- 2017-06-19 EP EP17881180.8A patent/EP3556387A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020510627A5 (https=) | ||
| Jin et al. | Gut microbes in cardiovascular diseases and their potential therapeutic applications | |
| Sahebkar et al. | New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease | |
| Avis et al. | Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia | |
| JP2020502154A5 (https=) | ||
| Arrigoni et al. | Pharmacogenetic foundations of therapeutic efficacy and adverse events of statins | |
| JP2020502156A5 (https=) | ||
| CA3018647C (en) | Pharmaceutical composition of a farnesoid x receptor agonist and a npc1l1 receptor inhibitor, and uses thereof | |
| JP2014508753A5 (https=) | ||
| JP2012525376A5 (https=) | ||
| US20200268770A1 (en) | Pharmaceutical composition used for treating metabolic syndrome disorders, infectious diseases, and complications thereof | |
| Liu et al. | Rivaroxaban suppresses the progression of ischemic cardiomyopathy in a murine model of diet-induced myocardial infarction | |
| Park | Intestinal and hepatic niemann-pick c1-like 1 | |
| Litwin et al. | Metabolic syndrome in children with chronic kidney disease and after renal transplantation | |
| JP2013503110A5 (https=) | ||
| JP2016513730A5 (https=) | ||
| Zong et al. | 18α‐glycyrrhetinic acid extracted from G lycyrrhiza radix inhibits proliferation and promotes apoptosis of the hepatic stellate cell line | |
| Hu et al. | LXRβ activation increases intestinal cholesterol absorption, leading to an atherogenic lipoprotein profile | |
| Wang et al. | Transintestinal cholesterol excretion: A secondary, nonbiliary pathway contributing to reverse cholesterol transport | |
| Trentman et al. | Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians | |
| Dash et al. | Increased intestinal P-glycoprotein expression and activity with progression of diabetes and its modulation by epigallocatechin-3-gallate: Evidence from pharmacokinetic studies | |
| Pinto et al. | Unfolded protein response: cause or consequence of lipid and lipoprotein metabolism disturbances? | |
| Chen et al. | Induction of the ER stress response in NRVMs is linked to cardiotoxicity caused by celastrol: Celastrol cardiotoxicity involves the ER stress response | |
| JP2021519321A (ja) | ペプチド含有製剤 | |
| Ruggenenti et al. | Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial |